Key Developments: Arena Pharmaceuticals Inc (ARNA.O)

ARNA.O on Nasdaq

4.14USD
25 Nov 2014
Price Change (% chg)

-- (--)
Prev Close
$4.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,281,983
52-wk High
$7.97
52-wk Low
$3.26

Search Stocks

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals issued composition of matter patent by United States Patent and Trademark Office for Ralinepag and Related Compounds
Tuesday, 25 Nov 2014 08:00am EST 

Arena Pharmaceuticals Inc:Says that US Patent and Trademark Office granted Arena U.S. Patent No. 8,895,776, entitled Modulators of the Prostacyclin (PGI2) Receptor Useful for Treatment of disorders related Thereto, covering ralinepag (formerly APD811), an orally available agonist of the prostacyclin (IP) receptor.Ralinepag is an investigational drug candidate being developed by Arena for the treatment of vasospastic diseases such as pulmonary arterial hypertension (PAH).Arena owns patents and pending patent applications covering compositions of matter for ralinepag and related compounds, as well as methods of treatment utilizing ralinepag and related compounds.Patent applications for ralinepag have been filed in 19 jurisdictions, including the United States, Europe, Japan and China.  Full Article

Arena Pharmaceuticals Inc and Eisai Inc report results of an investigational phase 2 trial of Lorcaserin HCl as an aid for smoking cessation
Monday, 3 Nov 2014 06:30am EST 

Arena Pharmaceuticals Inc and Eisai Inc:Says top-line results from Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking cessation.Says trial demonstrated statistically significant improvement over placebo in reducing number of patients who smoke after 12 weeks of treatment.Says detailed results of trial are expected to be presented at future scientific meeting.Lorcaserin is an investigational product for smoking cessation.Says efficacy and safety of lorcaserin for smoking cessation have not been established.Primary objective of trial was assessment of smoking cessation efficacy and primary endpoint was achieved.Secondary objectives for trial included assessment of body weight change and of safety and tolerability.At Week 12 in MITT population, there was statistically significant difference in weight between lorcaserin BID and placebo.  Full Article

Arena Pharmaceuticals Incs' APD811 granted orphan drug status for Pulmonary Arterial Hypertension
Tuesday, 2 Sep 2014 08:00am EDT 

Arena Pharmaceuticals Inc:Announced that US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for treatment of pulmonary arterial hypertension.  Full Article

Arena Pharmaceuticals Inc's subsidiary enters into marketing and supply agreement for BELVIQ with Teva Pharmaceutical Industries Limited's subsidiary
Monday, 21 Jul 2014 08:00am EDT 

Arena Pharmaceuticals Inc:Says its subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ with Teva Pharmaceutical Industries Limited's local Israeli subsidiary, Abic Marketing Limited.Under the agreement, Arena granted Abic the rights to market and distribute BELVIQ in Israel for weight loss or weight management in obese and overweight patients.Arena will manufacture finished drug product at its facility in Switzerland, which it will sell to Abic at a purchase price equal to a percentage of Abic's annual net sales of BELVIQ.Arena will receive an upfront payment, and is eligible to receive payments upon regulatory submission and regulatory approval of BELVIQ as well as one-time purchase price adjustment payments based on Abic's annual net sales.  Full Article

Arena Pharmaceuticals issued patent for APD371 by United States Patent and Trademark Office
Tuesday, 15 Jul 2014 04:32pm EDT 

Arena Pharmaceuticals Inc:Announces that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators, by the United States Patent and Trademark Office for APD371, an agonist of the cannabinoid receptor 2 (CB2).  Full Article

Arena Pharmaceuticals initiates phase 1b clinical trial of APD334 for autoimmune diseases
Tuesday, 3 Jun 2014 08:00am EDT 

Arena Pharmaceuticals Inc:Says initiation of dosing in an investigational Phase 1b clinical trial of APD334, a oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to evaluate the compound for the treatment of a number of autoimmune diseases.This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers.  Full Article

Arena Pharmaceuticals Inc Completes Phase 1b Clinical Trial Evaluating APD811 For Pulmonary Arterial Hypertension
Wednesday, 28 Aug 2013 08:30am EDT 

Arena Pharmaceuticals Inc announced the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The Company plans to initiate a Phase 2 clinical trial for APD811 in the first quarter of 2014. This randomized, double-blind and placebo-controlled Phase 1b clinical trial evaluated the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811. Arena previously evaluated single-ascending doses of APD811 in a Phase 1a clinical trial. In the Phase 1b clinical trial, 40 healthy volunteers received APD811 and 15 received placebo, and the safety profile of APD811 was characteristic of IP receptor agonists. No serious adverse events were observed, and the most frequent treatment-emergent adverse events were headache, nausea and jaw pain. The results of the Phase 1 program led to the decision to proceed with Phase 2 development of APD811, which will include further exploration of dosing regimens in PAH patients. PAH is a progressive, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs. The increased pressure strains the heart, which can limit physical activity, result in heart failure and reduce life expectancy.  Full Article

Arena Pharmaceuticals Inc Announces BELVIQ (Lorcaserin HCl) New Drug Submission In Canada
Wednesday, 26 Jun 2013 11:00am EDT 

Arena Pharmaceuticals Inc announced that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission (NDS) for BELVIQ (lorcaserin HCl) with Health Canada. BELVIQ is being evaluated in Canada as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adult obese patients (initial body mass index, or BMI, ≥ 30 kg/m2), or overweight patients (initial BMI ≥ 27 kg/m2) in the presence of at least one additional cardiovascular risk factor (e.g., hypertension, dyslipidemia, type 2 diabetes, or sleep apnea). In connection with the NDS, Arena will receive a payment of $500,000 from Eisai.  Full Article

Arena Pharmaceuticals Inc Initiates Phase1 Clinical Trial of APD334 for Autoimmune Diseases
Friday, 5 Apr 2013 08:00am EDT 

Arena Pharmaceuticals Inc announced the initiation of dosing in a Phase 1 clinical trial of APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1 trial will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD334 in up to 64 healthy adult volunteers.  Full Article

Photo

After slam dunk, NBA eyes growth in Mexico but no franchise yet

MEXICO CITY - Delighted following a packed house at Wednesday's regular clash between the Houston Rockets and Minnesota Timberwolves, the NBA is eyeing further growth in Mexico next year but any eventual franchise south of the border is still some ways off.

Search Stocks